Pre-saturation of HER2 in SKOV3 xenografts with anti-HER2 antibody trastuzumab significantly decreased (p < 0.00005) the tumor-associated radioactivity from 21 ± 6 to 0.33 ± 0.04%ID/g for 111In-DEAVDANS-ADAPT6-GSSC-DOTA and from19 ± 3 to 0.4 ± 0.1 for 99mTc-DEAVDANS-ADAPT6-GSSC (Fig. 5). The gene discussed is ERBB2; the disease is neoplasm.